Expansion Into Nuclear Energy And Life Sciences Will Strengthen Future Prospects

Shared on01 May 25
Fair value Increased 6.49%

Shared on23 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on17 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on09 Apr 25
Fair value Decreased 0.021%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on02 Apr 25
Fair value Decreased 7.60%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on26 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on19 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on12 Mar 25
Fair value Increased 1.65%

AnalystConsensusTarget has increased revenue growth from 2.9% to 6.8%, increased profit margin from 6.1% to 7.7% and decreased future PE multiple from 37.2x to 24.1x.